一种组合物及其改善胰岛素抵抗和降糖用途
By combining atractylodes lactone II and berberine with statins or fibrates, the limited efficacy of existing drugs has been addressed, achieving synergistic improvement in insulin resistance and hypoglycemic effects while reducing adverse reactions.
CN122398797APending Publication Date: 2026-07-17CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CN202610901146.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-06-22
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing drugs for improving insulin resistance have limited efficacy, cannot cover multiple system diseases simultaneously, and have many adverse reactions. Natural product combinations have advantages in multi-target and multi-pathway regulation.
Method used
A pharmaceutically acceptable dosage form was prepared by combining atractylodes lactone II and berberine (or a pharmaceutically acceptable salt thereof) in a ratio of 1:1 to 4:3, in combination with statins or fibrates, to improve insulin resistance and lower blood sugar.
Benefits of technology
The composition exhibits a synergistic effect at certain ratios, significantly improving insulin resistance, reducing glucose concentrations in the liver and blood, and reducing adverse reactions.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122398797A_ABST
Abstract
本发明公开了一种组合物及其改善胰岛素抵抗和降糖用途，属于化学领域。本发明请求保护一种组合物，包括成分（Ι）和成分（Ⅱ）：成分（Ι）为白术内酯II；成分（Ⅱ）为小檗碱，或小檗碱药学上可接受的盐。药理实验证明，该组合物具有改善胰岛素抵抗、降糖的作用，且组合物的成分配比在一定比例时呈现明显的协同作用。该组合物还可以进一步包含降脂成分。因此，本发明提供的组合物具有开发成预防和 / 或治疗胰岛素抵抗、降糖的药品的前景。
Need to check novelty before this filing date? Find Prior Art